GlassScriptPhysician profile
Ladan Abbasi
NPI 1689062952
$2,448.39
in general payments reported to CMS, 2019-2025
21 companies · $168 in 2025
The $168 reported for 2025 was more than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $831 · 2022: $875 · 2023: $409 · 2024: $165 · 2025: $168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $742.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $742.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $440.82 | 2021-2024 | Xarelto |
| Amgen INC. | $419.04 | 2021-2023 | Repatha |
| Novartis Pharmaceuticals Corporation | $394.71 | 2021-2022 | |
| Boston Scientific Corporation | $234.60 | 2022-2024 | Varithena Administration Pack |
| Amarin Pharma, INC. | $165.21 | 2021-2023 | |
| Atricure, INC. | $155.45 | 2023-2025 | Atriclip Laa Exclusion System, Epi-Sense Guided Coagulation System With Visitrax |
| Biotronik Nro, INC. | $141.31 | 2025 | Prospera |
| Esperion Therapeutics, INC. | $100.15 | 2021 | |
| Sanofi-Aventis U.S. LLC | $91.41 | 2022-2023 | |
| Tactile Systems Technology INC | $90.34 | 2022 | |
| Inspire Medical Systems, INC. | $32.11 | 2024 | Inspire |
| Merck Sharp & Dohme LLC | $27.55 | 2022-2023 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.20 | 2021-2022 | |
| Saluda Medical Americas, INC. | $20.83 | 2024 | Evoke |
| Angiodynamics, INC. | $18.16 | 2023 | Venacure 1470 Pro |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $17.54 | 2024 | Senza |
| Lexicon Pharmaceuticals, INC. | $17.20 | 2023 | Inpefa |
| Janssen Biotech, INC. | $15.10 | 2023 | Xarelto |
| Pfizer INC. | $14.37 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $14.18 | 2023 | Farxiga |
| Kowa Pharmaceuticals America, INC. | $12.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ladan Abbasi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.